Literature DB >> 11400254

Recognizing diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis.

M Sculpher1, A Gafni.   

Abstract

Public preferences are typically incorporated into cost-effectiveness analyses (CEA) on the basis of the average health state utilities of a sample of individuals drawn from the general public. The cost-effectiveness of a programme is then assessed on an 'all-or-nothing' basis: the programme is declared either cost-effective or not for all patients in clinically homogeneous sub-groups. However, this approach fails to recognize variability between individuals in their preferences. In this paper, we consider how diversity in the preferences of individuals can be handled within CEA when the public's preferences are considered appropriate for defining benefit, with the objective of increasing the efficiency of health care delivery. The concept of preference sub-group analysis is described and some of its implications are assessed. These include the methods that could be used to identify sub-groups from amongst public raters, the appropriate approach to eliciting preferences and the possible implications of preference sub-group analysis for clinical decision making. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2001        PMID: 11400254     DOI: 10.1002/hec.592

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  17 in total

Review 1.  Resource allocation, social values and the QALY: a review of the debate and empirical evidence.

Authors:  David L B Schwappach
Journal:  Health Expect       Date:  2002-09       Impact factor: 3.377

2.  Pharmacogenomics and the evolution of healthcare : is it time for cost-effectiveness analysis at the individual level?

Authors:  Mohan V Bala; Gary A Zarkin
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

3.  Optimal assignment of treatments to health states using a Markov decision model: an introduction to basic concepts.

Authors:  Mohan V Bala; Josephine A Mauskopf
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Lean systems approaches to health technology assessment: a patient-focused alternative to cost-effectiveness analysis.

Authors:  John F P Bridges
Journal:  Pharmacoeconomics       Date:  2006-12       Impact factor: 4.981

Review 5.  Acknowledging patient heterogeneity in economic evaluation : a systematic literature review.

Authors:  Janneke P C Grutters; Mark Sculpher; Andrew H Briggs; Johan L Severens; Math J Candel; James E Stahl; Dirk De Ruysscher; Albert Boer; Bram L T Ramaekers; Manuela A Joore
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981

6.  Validity and responsiveness of the EQ-5D and the KIDSCREEN-10 in children with ADHD.

Authors:  Clazien Bouwmans; Annemarie van der Kolk; Mark Oppe; Saskia Schawo; Elly Stolk; Michel van Agthoven; Jan Buitelaar; LeonaHakkaart van Roijen
Journal:  Eur J Health Econ       Date:  2014-12

7.  Subgroups and heterogeneity in cost-effectiveness analysis.

Authors:  Mark Sculpher
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 8.  The role of patient preferences in cost-effectiveness analysis: a conflict of values?

Authors:  John E Brazier; Simon Dixon; Julie Ratcliffe
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

9.  Recommendations for increasing the use of HIV/AIDS resource allocation models.

Authors:  Arielle Lasry; Anke Richter; Frithjof Lutscher
Journal:  BMC Public Health       Date:  2009-11-18       Impact factor: 3.295

10.  An evaluation of the effectiveness and cost effectiveness of the National Exercise Referral Scheme in Wales, UK: a randomised controlled trial of a public health policy initiative.

Authors:  Simon Mark Murphy; Rhiannon Tudor Edwards; Nefyn Williams; Larry Raisanen; Graham Moore; Pat Linck; Natalia Hounsome; Nafees Ud Din; Laurence Moore
Journal:  J Epidemiol Community Health       Date:  2012-05-10       Impact factor: 3.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.